Cantourage Group (HIGH) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
EBITDA increased by 45% year-over-year in Q2 2026, reaching EUR 2.9 million, despite a 21.9% decline in revenue to EUR 21.8 million.
Strategic focus on high-margin premium products in Germany improved earnings quality.
International markets, especially the United Kingdom and Poland, showed strong growth and now contribute over half of total revenue.
Financial highlights
Gross margin rose from 28.5% to 36.4% year-over-year in Q2 2026.
EBITDA margin improved from 7.0% to 13.1%.
Net cash position increased to EUR 9.3 million as of June 30, 2026, up from EUR 1.9 million a year earlier.
Equity ratio stood at 71.3% at the end of Q2 2026.
Outlook and guidance
The business model is described as internationally scalable, with a strong foundation for further European expansion.
Latest events from Cantourage Group
- Premium focus lifted Q2 EBITDA 45% YoY despite a 22% revenue decline.HIGH
Company presentation - Q3 EBITDA turned positive as higher margins and international markets offset German pricing pressure.HIGH
Q3 2026 - Profitable, asset-light cannabis platform drives growth with innovation, telemedicine, and strong margins.HIGH
Company presentation - Net profit surged to €210,989.14 in H1 2024, driven by higher revenue and one-time income.HIGH
H1 2024 - Revenue and net income grew strongly, with all earnings retained and a clean audit opinion.HIGH
H2 2024 - Q1 2025 revenue soared to EUR 25.6 million, quadrupling year-over-year on robust European demand.HIGH
Q1 2025 TU - Profitable, asset-light cannabis platform drives growth with innovation and telemedicine.HIGH
Investor presentation - Revenue and profit fell, but equity and liquidity remain robust amid higher compliance costs.HIGH
H1 2025 - Q2 2025 revenue more than doubled year-over-year, exceeding last year's total annual sales.HIGH
Q2 2025 TU